SK283088B6 - Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén - Google Patents

Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén Download PDF

Info

Publication number
SK283088B6
SK283088B6 SK1510-98A SK151098A SK283088B6 SK 283088 B6 SK283088 B6 SK 283088B6 SK 151098 A SK151098 A SK 151098A SK 283088 B6 SK283088 B6 SK 283088B6
Authority
SK
Slovakia
Prior art keywords
antigen
burgdorferi
mice
ospa
antibody
Prior art date
Application number
SK1510-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK151098A3 (en
Inventor
Markus M. Simon
Ulrich E. Schaible
Klaus Eichmann
Michael Kramer
Wallich Reinhard
Original Assignee
Max-Planck Gesellschaft Zur F�Rderung Der Wissenschaften E. V.
Deutsches Krebsforschungszentrum Stiftung Des �Ffentlichen Rec
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25885304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283088(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max-Planck Gesellschaft Zur F�Rderung Der Wissenschaften E. V., Deutsches Krebsforschungszentrum Stiftung Des �Ffentlichen Rec filed Critical Max-Planck Gesellschaft Zur F�Rderung Der Wissenschaften E. V.
Publication of SK151098A3 publication Critical patent/SK151098A3/sk
Publication of SK283088B6 publication Critical patent/SK283088B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1510-98A 1989-09-19 1990-09-19 Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén SK283088B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3931236 1989-09-19
DE4015911A DE4015911A1 (de) 1989-09-19 1990-05-17 Impfstoff gegen die lyme-krankheit

Publications (2)

Publication Number Publication Date
SK151098A3 SK151098A3 (en) 1999-04-13
SK283088B6 true SK283088B6 (sk) 2003-02-04

Family

ID=25885304

Family Applications (3)

Application Number Title Priority Date Filing Date
SK1511-98A SK283089B6 (sk) 1989-09-19 1990-09-19 Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie
SK1510-98A SK283088B6 (sk) 1989-09-19 1990-09-19 Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén
SK4560-90A SK456090A3 (en) 1989-09-19 1990-09-19 Vaccine against lyme disease and method for producing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK1511-98A SK283089B6 (sk) 1989-09-19 1990-09-19 Patogénny mikroorganizmus B.burgdorferi a spôsob jeho izolácie a rekultivácie

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK4560-90A SK456090A3 (en) 1989-09-19 1990-09-19 Vaccine against lyme disease and method for producing the same

Country Status (24)

Country Link
US (6) US5178859A (sh)
EP (5) EP0418827B1 (sh)
JP (3) JP3205932B2 (sh)
KR (2) KR100205462B1 (sh)
AT (4) ATE191499T1 (sh)
AU (1) AU651560B2 (sh)
CA (1) CA2025597C (sh)
CZ (2) CZ284616B6 (sh)
DE (5) DE4015911A1 (sh)
DK (4) DK0633313T3 (sh)
ES (4) ES2082812T3 (sh)
FI (1) FI102248B (sh)
GR (3) GR3018995T3 (sh)
HK (2) HK1002405A1 (sh)
HR (1) HRP940545B1 (sh)
HU (2) HU212716B (sh)
IE (1) IE903377A1 (sh)
NO (2) NO311767B1 (sh)
NZ (1) NZ235260A (sh)
PL (2) PL170229B1 (sh)
PT (1) PT95349B (sh)
SI (1) SI9011773B (sh)
SK (3) SK283089B6 (sh)
YU (2) YU48250B (sh)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) * 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
JPH06501382A (ja) * 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
ES2135411T3 (es) * 1991-08-15 1999-11-01 Smithkline Beecham Biolog Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
EP0540457A1 (en) * 1991-10-22 1993-05-05 Symbicom Ab Improvements in Borrelia burgdorferi diagnosis and prophylaxis
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5558993A (en) * 1994-06-17 1996-09-24 The Regents Of The University Of California Cloned Borrelia burgdorferi virulence protein
GB9511909D0 (en) * 1995-06-12 1995-08-09 Microbiological Res Authority Vaccine
DE69733944T3 (de) 1996-02-21 2012-07-26 The Board Of Regents, The University Of Texas System Vmp-ähnliche sequenzen von pathogener borrelia
DE19632862B4 (de) 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6458555B1 (en) * 1996-08-21 2002-10-01 Gerd Bach Cytologic method of examining mucous membranes
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19740735A1 (de) * 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
US6306623B1 (en) * 1998-02-24 2001-10-23 The University Of California Leptospiral major outer membrane protein LipL32
DK1100922T3 (da) 1998-07-31 2008-06-16 Gundersen Lutheran Medical Fou Anvendelser af én eller flere borreliacide epitoper på ydermembranprotein C fra Borrelia burgdorferi (OspC) som vaccine
WO2000056298A2 (en) * 1999-03-19 2000-09-28 Luitpold Pharmaceuticals, Inc. Treatment of lyme disease with polysulfated glycosaminoglycan formulations
US6592875B1 (en) 1999-06-21 2003-07-15 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2292762A3 (en) 2002-12-20 2012-12-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
EP2077856B1 (en) 2006-11-03 2015-08-12 Intervet International BV Canine lyme disease vaccine
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
CN102791727A (zh) * 2009-11-17 2012-11-21 爱贝斯股份有限公司 用于检测莱姆病抗体的肽和方法
US8758772B2 (en) 2011-11-04 2014-06-24 Abaxis, Inc. Peptides and methods for the detection of lyme disease antibodies
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US9610336B1 (en) * 2014-07-16 2017-04-04 Amiram Katz Immunotherapy for lyme disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4772464A (en) 1985-08-01 1988-09-20 Miles Laboratories, Inc. Protective antibodies to serotypic determinants of flagellar antigens
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
CA2072008C (en) * 1989-12-22 2003-01-28 Renate Fuchs Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains
JPH06501382A (ja) * 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
EP1016416A3 (en) * 1990-07-06 2002-10-23 Wyeth Vaccine against lyme disease and a challenge model for evaluating vaccine efficacy
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
ES2135411T3 (es) * 1991-08-15 1999-11-01 Smithkline Beecham Biolog Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.
DE69227844T2 (de) * 1991-08-27 1999-08-05 Novo Nordisk A/S, Bagsvaerd Waschmittelzusammensetzungen
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins

Also Published As

Publication number Publication date
HU905816D0 (en) 1991-03-28
ES2082812T3 (es) 1996-04-01
NO20014624D0 (no) 2001-09-24
YU49370B (sh) 2005-09-19
CZ456090A3 (cs) 1998-08-12
US5780030A (en) 1998-07-14
HRP940545A2 (en) 1997-04-30
ATE131732T1 (de) 1996-01-15
US5856447A (en) 1999-01-05
ES2129551T3 (es) 1999-06-16
FI904597A0 (fi) 1990-09-18
JP2001204467A (ja) 2001-07-31
YU9097A (sh) 1999-06-15
SI9011773B (en) 2001-12-31
EP0418827A1 (de) 1991-03-27
IE990173A1 (en) 2000-11-01
SK280285B6 (sk) 1999-11-08
EP0861664A2 (de) 1998-09-02
HK1002405A1 (en) 1998-08-21
CA2025597C (en) 2004-02-03
US5178859A (en) 1993-01-12
EP0643974A1 (de) 1995-03-22
YU48250B (sh) 1997-09-30
HU211228A9 (en) 1995-11-28
NZ235260A (en) 1993-04-28
PT95349B (pt) 1997-06-30
US5686267A (en) 1997-11-11
NO904062D0 (no) 1990-09-18
ES2145077T3 (es) 2000-07-01
DE4015911A1 (de) 1991-03-28
US6613331B1 (en) 2003-09-02
NO904062L (no) 1991-03-20
DE59009978D1 (de) 1996-02-01
JP2001069969A (ja) 2001-03-21
DK0643974T3 (da) 1999-09-06
DK0633028T3 (da) 2000-04-10
HUT59613A (en) 1992-06-29
FI102248B1 (fi) 1998-11-13
AU6244490A (en) 1991-03-28
KR910005889A (ko) 1991-04-27
AU651560B2 (en) 1994-07-28
GR3032010T3 (en) 2000-03-31
EP0633028B1 (de) 1999-11-17
CA2025597A1 (en) 1991-03-20
NO311767B1 (no) 2002-01-21
EP0633313A1 (de) 1995-01-11
DK0633313T3 (da) 2000-07-24
HRP940545B1 (en) 2000-06-30
IE903377A1 (en) 1991-04-10
DE59010903D1 (de) 2000-05-11
ES2141182T3 (es) 2000-03-16
CZ284616B6 (cs) 1999-01-13
FI102248B (fi) 1998-11-13
JP3418171B2 (ja) 2003-06-16
JP3205932B2 (ja) 2001-09-04
HU212716B (en) 1996-10-28
HK1013620A1 (en) 1999-09-03
GR3018995T3 (en) 1996-05-31
YU177390A (sh) 1993-05-28
DK0418827T3 (da) 1996-05-06
KR100202128B1 (en) 1999-06-15
NO20014624L (no) 1991-03-20
EP0633313B1 (de) 2000-04-05
JPH03209400A (ja) 1991-09-12
SK456090A3 (en) 1999-11-08
SK283089B6 (sk) 2003-02-04
DE59010863D1 (de) 1999-02-25
KR100205462B1 (ko) 1999-07-01
SI9011773A (sl) 1998-04-30
EP0643974B1 (de) 1999-01-13
JP3328644B2 (ja) 2002-09-30
SK151198A3 (en) 1999-04-13
EP0861664A3 (de) 1999-02-24
PL170229B1 (pl) 1996-11-29
ATE186646T1 (de) 1999-12-15
NO315905B1 (no) 2003-11-10
PL169804B1 (pl) 1996-09-30
US5434077A (en) 1995-07-18
CZ97095A3 (en) 1995-09-13
EP0418827B1 (de) 1995-12-20
DE59010888D1 (de) 1999-12-23
CZ284538B6 (cs) 1998-12-16
EP0633028A1 (de) 1995-01-11
SK151098A3 (en) 1999-04-13
PT95349A (pt) 1991-05-22
GR3033675T3 (en) 2000-10-31
ATE191499T1 (de) 2000-04-15
ATE175576T1 (de) 1999-01-15

Similar Documents

Publication Publication Date Title
SK283088B6 (sk) Spôsob získania antigénu, ktorý imunologicky reaguje s protilátkami proti B burgdorferi antigénom a spôsob výroby vakcíny obsahujúcej takýto antigén
US5747294A (en) Compositions and methods for the prevention and diagnosis of lyme disease
IE83320B1 (en) Vaccine against lyme disease
US5807685A (en) OspE, OspF, and S1 polypeptides in Borrelia burgdorferi
Jonson et al. Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1
MX2010010614A (es) Composiciones, metodos y kits.
US5543304A (en) 43 Kd protein vaccine and method for the production thereof
AU673912B2 (en) Vaccine against lyme disease
US6716591B1 (en) B. burgdorferi polypeptides
IE83340B1 (en) Vaccine against lyme disease